- Home
- PBA vs NTRA Comparison
PBA vs NTRA Comparison
Compare PBA & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- NTRA
- Stock Information
- Founded
- PBA 1997
- NTRA 2003
- Country
- PBA Canada
- NTRA United States
- Employees
- PBA N/A
- NTRA N/A
- Industry
- PBA Oil & Gas Production
- NTRA Medical Specialities
- Sector
- PBA Energy
- NTRA Health Care
- Exchange
- PBA Nasdaq
- NTRA Nasdaq
- Market Cap
- PBA 21.6B
- NTRA 21.7B
- IPO Year
- PBA N/A
- NTRA 2015
- Fundamental
- Price
- PBA $37.96
- NTRA $168.02
- Analyst Decision
- PBA
- NTRA Strong Buy
- Analyst Count
- PBA 0
- NTRA 16
- Target Price
- PBA N/A
- NTRA $193.50
- AVG Volume (30 Days)
- PBA 1.4M
- NTRA 1.2M
- Earning Date
- PBA 11-04-2025
- NTRA 08-07-2025
- Dividend Yield
- PBA 5.25%
- NTRA N/A
- EPS Growth
- PBA N/A
- NTRA N/A
- EPS
- PBA 2.18
- NTRA N/A
- Revenue
- PBA $5,911,897,112.00
- NTRA $1,964,250,000.00
- Revenue This Year
- PBA $8.57
- NTRA $23.93
- Revenue Next Year
- PBA N/A
- NTRA $15.60
- P/E Ratio
- PBA $17.46
- NTRA N/A
- Revenue Growth
- PBA 20.59
- NTRA 44.38
- 52 Week Low
- PBA $34.13
- NTRA $110.57
- 52 Week High
- PBA $43.44
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- PBA 59.32
- NTRA 62.59
- Support Level
- PBA $37.22
- NTRA $156.71
- Resistance Level
- PBA $38.01
- NTRA $170.72
- Average True Range (ATR)
- PBA 0.49
- NTRA 4.62
- MACD
- PBA 0.07
- NTRA 0.39
- Stochastic Oscillator
- PBA 82.12
- NTRA 80.73
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.